Category: Side Effects
SARS-CoV-2 can infect and replicate in retinal cells
SARS-CoV-2 infects retinal cells, especially retinal ganglion cells, but also light-sensitive cells. More...
Preprint: Intranasal delivery of SARS-CoV-2 Spike protein is sufficient to cause olfactory damage
We hypothesize that SARS-CoV-2 spike (S) protein is sufficient to cause olfactory damage and olfactory dysfunction. More...
Preprint: Multi-organ impairment and Long COVID
“3 in 5 people with Long COVID have impairment in at least one organ, and 1 in 4 have impairment in two or more organs, in some cases without symptoms.” More...
WHO: Covifenz tobacco vaccine won’t get approval for emergency use
The World Health Organization has said that Quebec’s plant-based COVID-19 vaccine will “very likely” not be approved for emergency use. More...
Preprint: Beta-amyloid deposits found in brains of young Covid patients
This report describes a relatively young (< 60 y/o) COVID patient without known clinical evidence of dementia who at autopsy had large numbers of thioflavin-negative, immunoreactive β-amyloid deposits in her neocortex. More...
Denmark: 30% of non-hospitalized Covid cases still have at least one symptom after six months
Almost 30% of study participants still experienced at least one physical symptom 6-12 months after previous infection. More...
Long Covid: Tissue damage several weeks after the first diagnosis of SARS-CoV-2 infection
Our data provide evidence not only of long-term postmortem persisting SARS-CoV-2 RNA but also of tissue damage several weeks after the first diagnosis of SARS-CoV-2 infection. More...
Preprint: Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the emergence of the Omicron variant
For children 5-11, VE against cases declined from 65% to 12% by 28-34 days. More...
Preprint: Intracellular Reverse Transcription into DNA of mRNA Vaccine
We show that BNT162b2 mRNA is reverse transcribed intracellularly into DNA in as fast as 6 hours upon BNT162b2 exposure. More...
Covid-19 can lead to delusions and aggression *1 UPDATE*
Drug treatment should be started in Covid-19 patients with delirium who present agitation, aggression, hallucinations, and delusions which pose a risk of imminent harm to others. More...